Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab and Guselkumab in Active Rheumatoid Arthritis
NCT01645280Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2012
- Primary completion
- Dec 2013
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of ustekinumab, guselkumab in rheumatoid arthritis (RA), sponsored by Janssen Pharmaceutical. Started Aug 2012; status: completed.
02
Drugs
ustekinumabguselkumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01645280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01645280.